Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.
article
OA: closed
CC0
⤵ 77 in-corpus citations
AI-generated summary
Six-month GnRH agonist treatment in women with endometriosis suppressed disease visually and reduced pain, but induced menopausal side effects and occult endometriosis persistence.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Sixteen women with endometriosis were treated with daily subcutaneous injections of a potent agonist of gonadotropin-releasing hormone (GnRH) for six months. Ovarian estrogen secretion was reduced to castrate levels during most of the course of treatment. Blinded evaluation of laparoscopic photographs confirmed marked suppression of visually apparent disease, but biopsy specimens showed occult, inactive endometriosis in most cases. Marked pain relief was noted by all patients. As a result of this "medical oophorectomy," the women experienced severe hot flashes, and many had insomnia and emotional disturbances. Vaginal cytology showed menopausal changes but related symptoms were generally mild. Calcium excretion rose to menopausal levels. High-density lipoprotein and total cholesterol remained unchanged. These results indicate that GnRH agonist administration has impressive effects on endometriotic implants, and these actions may be enhanced with longer therapy. Further development of this new form of therapy should involve either use of lesser degrees of ovarian suppression or adjunctive therapy to counter the side effects of "medical oophorectomy."
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (50)
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
- The Importance of a Multi-Disciplinary Approach to the Endometriotic Patients: The Relationship between Endometriosis and Psychic Vulnerability 2021
- Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis 2016
- Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis 2015
- An update on the pharmacological management of endometriosis 2013
- Psychosomatic Aspects 2011
- The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis 2010
- Effect of French maritime pine bark extract on endometriosis as compared with leuprorelin acetate. 2007
- Depressão maior e supressão hormonal: resposta com a nortriptilina 2007
- Intervenção multiprofissional em grupo as mulheres com endometriose 2007
- Depression in women with endometriosis with and without chronic pelvic pain 2006
- Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary 2004
- Avaliação da prevalencia de depressão em mulheres com endometriose atraves do BDI 2003
- Avaliação da freqüência de depressão em pacientes com endometriose e dor pélvica 2002
- Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome 2002
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Tratamento de endometriomas ovarianos com implantes subcutâneos de ST-1435 (Elcometrina) 1999
- Current Drug Therapy Recommendations for the Treatment of Endometriosis 1999
- Sertraline in the Treatment of Depression Associated with Gonadotropin-Releasing Hormone Agonist Therapy 1998
- Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study 1998
- The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover 1998
- Cost comparisons between nafarelin and leuprolide in the treatment of endometriosis 1998
- GnRH agonists and add‐back therapy: is there a perfect combination? 1998
- Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata 1997
- Tratamiento endocrinológico de la endometriosis 1997
- Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. 1996
- Prognostic application of magnetic resonance imaging in patients with endometriomas treated with gonadotrophin-releasing hormone analogue 1996
- Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis 1996
- A serial section study of visually normal posterior pelvic peritoneum from baboons (Papio cynocephalus, Papio anubis) with and without spontaneous minimal endometriosis 1995
- Endocrine effects of GnRH analogue with low‐dose hormone replacement therapy in women with endometriosis 1995
- Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy 1995
- Goserelin (Zoladex) and the skeleton 1994
- 9 Endometriosis: Medical therapy 1993
- 1 Is endometriosis a disease? 1993
- GnRH Agonists in the Treatment of Endometriosis 1993
- Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study 1993
- Gonadotropin-releasing hormone agonist plus estrogen-progestin “add-back” therapy for endometriosis-related pelvic pain 1993
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. 1992
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone 1992
- Endometriosetherapie mit Enantone®-Gyn Monats-Depot 1992
- Direct effects of medroxyprogesterone acetate, danazol, and leuprolide acetate on endometrial stromal cell proliferation in vitro 1992
- Treatment of endometriosis 1992
- Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992
- Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy 1992
- Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat 1991
- Endometriosis and adenomyosis 1991
- Medical treatment of mild endometriosis associated with infertility 1991
- GnRH analogues in the treatment of endometriosis — rationale and efficacy 1991
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass 1991
Source provenance
- europepmc
- last seen: 2026-08-09T06:10:49.860119+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:30.565292+00:00
License: CC0
· commercial use OK